- Home
- MNMD vs ATEX Comparison
MNMD vs ATEX Comparison
Compare MNMD & ATEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- ATEX
- Stock Information
- Founded
- MNMD 2019
- ATEX 1997
- Country
- MNMD United States
- ATEX United States
- Employees
- MNMD N/A
- ATEX N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- ATEX Telecommunications Equipment
- Sector
- MNMD Health Care
- ATEX Telecommunications
- Exchange
- MNMD Nasdaq
- ATEX Nasdaq
- Market Cap
- MNMD 509.2M
- ATEX 468.9M
- IPO Year
- MNMD N/A
- ATEX N/A
- Fundamental
- Price
- MNMD $9.76
- ATEX $21.20
- Analyst Decision
- MNMD Strong Buy
- ATEX Buy
- Analyst Count
- MNMD 6
- ATEX 2
- Target Price
- MNMD $24.67
- ATEX $64.00
- AVG Volume (30 Days)
- MNMD 1.3M
- ATEX 207.2K
- Earning Date
- MNMD 07-31-2025
- ATEX 08-05-2025
- Dividend Yield
- MNMD N/A
- ATEX N/A
- EPS Growth
- MNMD N/A
- ATEX N/A
- EPS
- MNMD N/A
- ATEX N/A
- Revenue
- MNMD N/A
- ATEX $6,031,000.00
- Revenue This Year
- MNMD N/A
- ATEX $5.17
- Revenue Next Year
- MNMD N/A
- ATEX $2.92
- P/E Ratio
- MNMD N/A
- ATEX N/A
- Revenue Growth
- MNMD N/A
- ATEX 43.90
- 52 Week Low
- MNMD $4.70
- ATEX $21.05
- 52 Week High
- MNMD $10.44
- ATEX $42.91
- Technical
- Relative Strength Index (RSI)
- MNMD 71.46
- ATEX 22.05
- Support Level
- MNMD $9.54
- ATEX $23.96
- Resistance Level
- MNMD $10.09
- ATEX $24.81
- Average True Range (ATR)
- MNMD 0.47
- ATEX 0.80
- MACD
- MNMD 0.18
- ATEX -0.15
- Stochastic Oscillator
- MNMD 83.89
- ATEX 3.99
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.